ReddyPort announced today that the US Food and Drug Administration (FDA) granted 510(k) premarket clearance for the ReddyPort elbow device used in non-invasive ventilation (NIV).

“ReddyPort’s patented elbow is central to the eco-system we are building to help mitigate clinical obstacles tied to NIV therapy from dry-mouth, oral biofilm accumulation to speech recognition,” says Tony Lair, ReddyPort CEO.

ReddyPort’s elbow features a self-sealing valve that provides seamless oral access to the patient’s mouth without the need for mask removal, alleviating the risk of therapeutic pressure loss and maintaining lung compliance.

Read More